Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Diluted EPS of $1.68 per share for fiscal year 2025.
CATALYST PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.68 | +28.2% |
| 2024 | $1.31 | +107.9% |
| 2023 | $0.63 | -16.0% |
| 2022 | $0.75 | +102.7% |
| 2021 | $0.37 | -47.9% |
| 2020 | $0.71 | +136.7% |
| 2019 | $0.30 | +190.9% |
| 2018 | -$0.33 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.42 | +20.0% | +2.4% |
| June 30, 2025 | $0.41 | +24.2% | -8.9% |
| March 31, 2025 | $0.45 | +136.8% | +28.6% |
| September 30, 2024 | $0.35 | +220.7% | +6.1% |
| June 30, 2024 | $0.33 | +0.0% | +73.7% |
| March 31, 2024 | $0.19 | -26.9% | +165.5% |
| September 30, 2023 | -$0.29 | -245.0% | -187.9% |
| June 30, 2023 | $0.33 | +65.0% | +26.9% |
- CATALYST PHARMACEUTICALS, INC. showed an increase of +28.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2018–2025 period, CATALYST PHARMACEUTICALS, INC.’s diluted eps has grown by 609.1% (from $0.33 per share (loss) to $1.68 per share).
- The most recent figure is from CATALYST PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: